Dr. Reddy’s intros generic Renvela
HYDERABAD, India, and PRINCETON, N.J. — Dr. Reddy’s Laboratories recently launched its generic of Renvela (sevelamer carbonate) tablets. The drug is indicated to control serum phosphorus in adults and children ages 6 years and older with chronic kidney disease who are on dialysis.
“We are very pleased to bring Sevelamer Carbonate Tablets to market at this time,” Dr. Reddy’s EVP and head of North American generics Alok Sonig said. “This launch represents Dr. Reddy’s expertise and commitment to provide affordable alternatives for complex, limited-competition products to market.” This is the Company’s eighth overall and fourth limited-competition launch this fiscal year.
The Dr. Reddy’s generic is available in 800-mg dosage strength in 270-count bottles. For the 12 months ended July 2017, the drug had U.S. sales of roughly $1.88 billion, according to QuintilesIMS data.